NBP SCHEDULE 13D/A: Insider sale planned
Filed with the SEC on · accession 0000919574-26-007454
NBP filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 5, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
A reporting person sold 200,000 ADSs of NovaBridge Biosciences on 11/05/2026 at $1.01 per ADS in an open-market transaction, as disclosed in a Schedule 13D amendment.
Key details
✦ Ask GOAX AI about this filing — what it means for NBP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NBP?
Click hereFrequently asked questions
What did NBP file with the SEC on Nov 5, 2026?
NBP filed a SCHEDULE 13D/A (Insider sale planned). A reporting person sold 200,000 ADSs of NovaBridge Biosciences on 11/05/2026 at $1.01 per ADS in an open-market transaction, as disclosed in a Schedule 13D amendment.
How do I read a SCHEDULE 13D/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).
Other NBP SEC filings
Get alerts when NBP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days